Nadofaragene firadenovec
- Generic Name
- Nadofaragene firadenovec
- Brand Names
- Adstiladrin
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1823059-12-6
- Unique Ingredient Identifier
- 0OOS09O1FH
- Background
Nadofaragene firadenovec (nadofaragene firadenovec-vncg) is a recombinant non-replicating adenovirus serotype 5 vector containing a transgene encoding human interferon alfa-2b (IFNα2b). It was approved by the FDA on December 2022 for the treatment of high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcino...
- Indication
Nadofaragene firadenovec is indicated for the treatment of adult patients with high-risk Bacillus CalmetteGuérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors.
- Associated Conditions
- High risk BCG-unresponsive non-muscle invasive bladder cancer
- Associated Therapies
- -
Managing BCG-Unresponsive NMIBC: Treatment Strategies, Progression, and Emerging Therapies
Discussions on novel treatments for BCG-unresponsive bladder cancer, including CD40 antibody, nadofaragene firadenovec, Anktiva (N-803), cretostimogene, and additional BCG, highlighting their efficacy and safety.
Vikram Narayan, MD, on cystectomy outcomes in nadofaragene-treated patients
Dr. Vikram M. Narayan discusses a study on nadofaragene firadenovec-vncg treatment in BCG-unresponsive non–muscle-invasive bladder cancer, finding that 2/3 of patients with complete response at 3 months avoided cystectomy at 60 months, and only 6 of 44 cystectomy patients had muscle-invasive cancer.
Ferring Advances Three Studies in ADSTILADRIN® (nadofaragene firadenovec-vncg ...
Ferring Pharmaceuticals advances three ADSTILADRIN clinical trials: two in NMIBC and one in UTUC. Researchers will present ADSTILADRIN study protocol for IR NMIBC and five-year CFS data at SUO 2024.
Related Clinical Trials:
Ferring bolsters Adstiladrin production with Finland expansion
Ferring's 25,000 sqm facility, approved by FDA in June 2023, produces adenovirus vector-based gene therapy Adstiladrin. A fill/finish plant in New Jersey is nearing completion. The unit aims for LEED certification with sustainable energy solutions. Adstiladrin, FDA-approved in 2022, became fully available in the US in January 2024. Ferring partnered with SK pharmteco in April 2024 for commercial-manufacturing scale-up.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath